Hikma Pharmaceuticals PLC (HIK) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to HECMA FY24 results. My name is Ada, and I will be the operator for today's call. If you would like to ask a question during the presentation, you may do so by pressing star followed by 1 on your telephone keypad. I will now hand you over to CEO, Riyadh Mishlawi. Riyadh, please go ahead. Okay, well, good morning, everyone. Thank you very much for coming. Thank you very much for being online to listen to this. I have to introduce my – I should introduce my colleagues. I'm usually here with Khaled, but this time we're all together, so you'll have a chance to ask directly to the presidents and the responsibles of each of our divisions. So starting with Susan, head of the investor relations. Bill Larkin, he's head of the injectables division. Khaled Nebulsi, as you all know, he's the CFO. Madem Darwaza, he's president and vice chair of MENA. And we have also Hafron. She is the president of the generics division. I have to start to say that we had a fantastic year this year. It's been a year since I've taken over the CEO position, and not only that, but also Three of the people that we have in front of you here had their first year in the positions that they are in. Halfron had joined us in April, and Bill took this position, replacing me when I took the CEO. So despite new management, we also had added new management into the EC. We managed to work very well together. We managed to really do a lot of things that is part of the execution of the strategy that we had. And I believe we had really a stellar year. A lot of things we had done in preparing for the medium term and the long term for the company. So let me start with the year. So I think we had a great momentum here. We had excellent results. We were well ahead of our original guidan...